ImmunoCAP Specific IgG4

Print Print icon Tell a friend Tell a friend icon
ImmunoCAP Specific IgG4 is an in vitro test system for the quantitative measurement of antigen specific IgG4 antibodies in humanserum and plasma. ImmunoCAP Specific IgG4 assay is to be used with the instrument ImmunoCAP 100E. ImmunoCAP Specific IgG4 is intended for in vitro diagnosis.
 
The measurements of specific IgG and/or IgG4 antibodies have been used in clinical studies of different allergic diseases such as asthma, rhinitis, urticaria, eczema and gastrointestinal disorders but also in different lung diseases, e.g. allergic alveolitis, aspergilloma and aspergillosis (1-12). In monitoring immunotherapy with inhalants and hymenoptera venoms increased levels of specific IgG and/or IgG4 are generally seen, but a definitive correlation with the clinical outcome has not been shown (1-7).

In some studies antigen specific IgG4 antibodies have been measured in patients with food allergy or intolerance (8). It is generally believed that specific IgG and IgG4 antibodies are biomarkers of antigen exposure (9-10). Allergen specific IgG4 antibodies may also have a role in immune deviation and development of tolerance (1, 3, 11-12).

References:

    1. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol. 2004 Jun;113:1025-34.
    2. Schiavino D, Nucera E, Pollastrini E, De Pasquale T, Buonomo A, Bartolozzi F, Lombardo C, Roncallo C,Patriarca G. Specific ultrarush desensitization in Hymenoptera venom-allergic patients. Ann Allergy Asthma Immunol. 2004 Apr;92:409-13.
    3. Jutel M, Akdis M, Blaser K, Akdis CA. Are regulatory Tcells the target of venom immunotherapy? Curr Opin Allergy Clin Immunol. 2005 Aug;5:365-9.
    4. Nagata M, Yamamoto H, Tabe K, Kimura I, Houya I, Kuramitso K, et al. Effect of Rush Immunotherapy in House-Dust-Mite (HDM) - Sensitive Adult Bronchial Asthma: Changes in In-Vivo and In-Vitro Responses toHDM. Intern Med 1993;32(9):702-9.
    5. Gehlhar K, Schlaak M, Becker W, Bufe A. Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergenspecific IgG4 to IgG1 correlates with clinical outcome. Clin Exp Allergy 1999; 29:497-506.
    6. Lima MT, Wilson D, Pitkin L et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: arandomized controlled trial. Clin Exp Allergy 2002;32:507-14.
    7. Ewbank PA, Murray J, Sanders K, Curran-Everett D, Dreskin S, Nelson HS. A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract. J Allergy Clin Immunol 2003; 111:155-61.
    8. Garcia BE, Sanz ML, Fernández M, Dièguez I, Oehling A. Value of IgG4 antibodies against food in atopic dermatitis. Allergol Immunopathol 1990;18(4):187-90.
    9. Tomee JFC, Dubois AEJ, Koëter GH, Beaumont F, vander Werf TS, Kauffman HF. Specific IgG4 Responses during Chronic and Transient Antigen Exposure inAspergillosis. Am J Respir Crit Care Med 1996;153:1952-7.
    10. Homburger HA, Mauer K, Sachs MI, O'Connell EJ, JacobGL, Caron J. Serum IgG4 concentrations and allergen-specific IgG4 antibodies compared in adults and childrenwith asthma and nonallergic subjects. J Allergy Clin Immunol 1986;77:427-34.
    11. Platts-Mills T, Vaughan J, Squillace S, Woodfolk J, SporikR. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a populationbasedcross-sectional study. Lancet 2001; 357:752-6.
    12. E. C. Matsui, G. B. Diette, E. J. M. Kropw, R. C. Aalberse, A. L. Smith, J. Curtin-Brosnan P. A. Eggleston. Mouse allergen-specific immunoglobulin G and immunoglobulinG4 and allergic symptoms in immunoglobulin E-sensitized laboratory animal workers. Clin Exp Allergy 2005; 35:1347-135313.NCCLS. Protocols for Determination of Limits of Detec-tion and Limits of Quantitation; Approved Guideline.NCCLS document EP17-A (ISBN 1-56238-551-8) October 2004.